Skip to content

Diagnosis and treatment of IgE-related salivary gland diseases

Antiallergic therapy of primary IgE-related salivary gland diseases

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032780
Enrollment
Unknown
Registered
2020-05-10
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Salivary gland disease

Interventions

Experimental group:antiallergic therapy

Sponsors

Peking University Hospital of Stomatology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who have been treated in oral and maxillofacial surgery of Peking University Hospital of Stomatology, with swelling of salivary glands, allergic history or symptoms, elevated serum and tissue IgE, and cannot be diagnosed as other IgE-related salivary gland diseases.

Exclusion criteria

Exclusion criteria: 1. Patients who have been diagnosed as other autoimmune diseases or allergic diseases and receiving other antiallergic or immunoregulatory treatments; 2. Patients with severe systemic diseases that cannot be effectively controlled; 3. Patients with obvious symptoms of allergic diseases that may cause serious systemic symptoms and need other anti-allergic treatment; 4. Patients who cannot be followed up and visited on time.

Design outcomes

Primary

MeasureTime frame
serum IgE level;salivary gland volumn;

Secondary

MeasureTime frame
Subjective scale;

Countries

China

Contacts

Public ContactGuangyan Yu

Peking University Hospital of Stomatology

gyyu@263.net+86 13501067548

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026